Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism

Regulatory Peptides

Volumn 125, Issue 1-3, 2005, Pages 173-177

  Nyström, Thomas ^a   Gonon, Adrian T ^b   Sjöholm, Åke ^a   Pernow, John ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cyclic AMP; Endothelial function; Exendin; GLP 1; Nitric oxide; Vasorelaxation

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; CONTROLLED STUDY; CORONARY BLOOD VESSEL; ENDOTHELIUM CELL; FEMORAL ARTERY; HEART PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULARIZATION;

ACETYLCHOLINE; ANIMALS; ARTERIES; CARDIOTONIC AGENTS; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMORAL ARTERY; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROARGININE; PEPTIDE FRAGMENTS; POTASSIUM; PROTEIN PRECURSORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON;

EID: 9944251347     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2004.08.024     Document Type: Article

References (18)

1. M.K. Gutniak, H. Larsson, S.J. Heiber, O.T. Juneskans, J.J. Holst, and B. Ahren Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet Diabetes Care 19 1996 843 848
2. J. Rachman, and R.C. Turner Drugs on the horizon for treatment of type 2 diabetes Diabet. Med. 12 1995 467 478
3. M. Gutniak, C. Orskov, J.J. Holst, B. Ahren, and S. Efendic Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus N. Engl. J. Med. 326 1992 1316 1322
4. M.A. Nauck, D. Wollschlager, J. Werner, J.J. Holst, C. Orskov, and W. Creutzfeldt Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM Diabetologia 39 1996 1546 1553
5. W.O. Creutzfeldt, N. Kleine, B. Willms, C. Orskov, J.J. Holst, and M.A. Nauck Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7-36) amide in type I diabetic patients Diabetes Care 19 1996 580 586
6. M. Zander, S. Madsbad, J.L. Madsen, and J.J. Holst Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 359 2002 824 830
7. T. Tolessa, M. Gutniak, J.J. Holst, S. Efendic, and P.M. Hellstrom Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin J. Clin. Invest. 102 1998 764 774
8. B.P. Bullock, R.S. Heller, and J.F. Habener Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor Endocrinology 137 1996 2968 2978
9. J.M. Barragan, R.E. Rodriguez, and E. Blazquez Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats Am. J. Physiol. 266 1994 E459 E466
10. J.M. Barragan, J. Eng, R. Rodriguez, and E. Blazquez Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats Am. J. Physiol. 277 1999 E784 791
11. H. Yamamoto, C.E. Lee, J.N. Marcus, T.D. Williams, J.M. Overton, and M.E. Lopez Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons J. Clin. Invest. 110 2002 43 52
12. G. Richter, O. Feddersen, U. Wagner, P. Barth, R. Goke, and B. Goke GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery Am. J. Physiol. 265 1993 L374 L381
13. H.A. Golpon, A. Puechner, T. Welte, P.V. Wichert, and C.O. Feddersen Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat Regul. Pept. 102 2001 81 86
14. L.A. Nikolaidis, S. Mankad, G.G. Sokos, G. Miske, A. Shah, and D. Elahi Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 2004 962 965
15. S. Makimattila, and H. Yki-Jarvinen Endothelial dysfunction in human diabetes Curr. Diabetes Rep. 2 2002 26 36
16. M.B. Toft-Nielsen, S. Madsbad, and J.J. Holst Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients Diabetes Care 22 1999 1137 1143
17. M. Yu, C. Moreno, K.M. Hoagland, A. Dahly, K. Ditter, and M. Mistry Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats J. Hypertens. 21 2003 1125 1135
18. L. Hansen, B. Hartmann, H. Mineo, and J.J. Holst Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum Regul. Pept. 118 2004 11 18